Lifecore Biomedical, Inc. Securities Fraud Lawsuit: A Call to LFCR Investors

Unveiling Allegations

LOS ANGELES, Aug. 30, 2024 — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have an opportunity to lead the securities fraud class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) LFCR.

Key Timeline and Deadline

Class Period: October 7, 2020 – March 19, 2024
Lead Plaintiff Deadline: September 27, 2024

The Allegations

If you wish to serve as lead plaintiff of the Lifecore lawsuit, you can submit your contact information. The complaint filed alleges that throughout the Class Period, Defendants withheld crucial information from investors relating to Lifecore’s financial reporting and internal controls.

Opportunity for Investors

Lifecore’s purported remediation efforts were deemed ineffective, impacting the accuracy of financial statements and leading to potential restatements. This situation impaired Lifecore’s ability to comply with SEC regulations, resulting in misleading statements about the Company’s financial well-being.

Call to Action

To be part of the class action, no immediate action is required. For further details or inquiries, interested parties can contact Glancy Prongay & Murray LLP.

Stay Updated

Follow for updates on LinkedIn, Twitter, or Facebook regarding this matter. Remember, you may choose to take action now or remain an absent member of the class action.

Information and Assistance

For more details, including questions or guidance on the pending class action lawsuit, please reach out to Glancy Prongay & Murray LLP. Remember that this press release may be considered Attorney Advertising in some regions under applicable laws.